The best indicator for Biogen (BIIB)
We backtested 20 indicators across daily, weekly and hourly charts on real Biogen (BIIB) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Bollinger Mean-Reversion
On the weekly chart, this is the strongest risk-adjusted edge we found for Biogen (BIIB) over ~34.8 years — trailing buy-and-hold by 6.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 20/50 Cross | Weekly | 11.2% | 0.46 | -86.4% | 35.7% | 14 | -1.5% |
| 2 | EMA 50/200 Cross | Daily | 8.7% | 0.41 | -85.0% | 40.7% | 27 | -4.0% |
| 3 | Bollinger Mean-Reversion ✓ | Weekly | 6.5% | 0.41 | -51.4% | 73.1% | 26 | -6.1% |
| 4 | CCI ✓ | Weekly | 6.9% | 0.37 | -65.2% | 70.6% | 34 | -5.7% |
| 5 | Heikin-Ashi Trend | Weekly | 7.5% | 0.37 | -88.6% | 46.0% | 311 | -5.2% |
| 6 | EMA 20/50 Cross | Daily | 6.6% | 0.36 | -86.8% | 36.6% | 93 | -6.0% |
| 7 | WaveTrend (8/6/4) ✓ | Daily | 6.6% | 0.36 | -75.6% | 65.4% | 133 | -6.0% |
| 8 | RSI Trend (>50) | Weekly | 6.5% | 0.35 | -93.5% | 41.6% | 101 | -6.2% |
| 9 | SMA 50/200 Cross | Daily | 5.6% | 0.34 | -86.2% | 27.6% | 29 | -7.0% |
| 10 | Stochastic ✓ | Daily | 5.9% | 0.34 | -81.9% | 65.7% | 172 | -6.7% |
| 11 | CCI ✓ | Daily | 6.3% | 0.34 | -70.6% | 67.1% | 173 | -6.4% |
| 12 | Holy Grail Confluence ✓ | Daily | 5.5% | 0.32 | -56.5% | 68.8% | 48 | -7.2% |
| 13 | Donchian Midline | Weekly | 5.1% | 0.32 | -86.5% | 41.8% | 98 | -7.6% |
| 14 | MACD | Weekly | 4.8% | 0.31 | -77.4% | 44.4% | 72 | -7.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Biogen (BIIB), Bollinger Mean-Reversion on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.